AKBA - Akebia Therapeutics, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Akebia Therapeutics, Inc.

245 First Street
Suite 1400
Cambridge, MA 02142
United States
617 871 2098

Full-time employees204

Key executives

NameTitlePayExercisedYear born
Mr. John P. Butler MBACEO, Pres & Director1.29MN/A1964
Mr. David A. SpellmanPrincipal Accounting Officer, Sr. VP, CFO & Treasurer961.92kN/A1976
Mr. Michel DahanSr. VP & COO734.73kN/A1979
Ms. Nicole R. HadasSr. VP, Chief Legal Officer & Sec.687.38kN/A1973
Dr. Steven Keith BurkeSr. VP of R&D and Chief Medical Officer766.57kN/A1961
Tracey VetterickVP of Portfolio Strategy & Corp. Admin.N/AN/AN/A
Mercedes CarrascoDirector of Corp. CommunicationsN/AN/AN/A
Mr. Douglas Jermasek M.B.A.VP of Marketing & StrategyN/AN/A1961
Ms. Meredith BowmanSr. VP of PeopleN/AN/AN/A
Ms. Kimberly GarkoSr. VP of Quality, Manufacturing & Pharmaceutical Devel.N/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Akebia Therapeutics, Inc.’s ISS governance QualityScore as of 1 June 2023 is 7. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.